Extended report
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:

    Dear Editor,

    Many thanks for the very interesting letter from Abud-Mendoza, highlighting their work in Mexico where they have successfully used rituximab in the treatment of both lupus nephritis and systemic lupus.
    Their initial report from 2006 [1] used rituximab as a treatment for refractory lupus nephritis and showed very detailed work on lymphocytes after rituximab administration. Supporting our data, th...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Are steroids required for therapy induction and relapses in lupus nephritis?
    • Carlos Abud-Mendoza, Proffesor
    • Other Contributors:
      • Carlos Abud-Mendoza, MD and Roberto Gonzalez Amaro MD

    Dear Editor,

    “A finger in the wound” is put by Condon et al. in their very interesting paper treating severe lupus nephritis with rituximab and mycophenolate, additionally to i.v. methyl-prednisolone, but not long-term oral steroids, achieving a good clinical response in most patients. 1

    Rheumatologists and nephrologists have the notion that glucocorticoids are the cornerstone for the treatment of autoimmune disea...

    Show More
    Conflict of Interest:
    None declared.